Danielle Burkhalter Sells 7,736 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Danielle Burkhalter sold 7,736 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $13.60, for a total value of $105,209.60. Following the completion of the sale, the insider directly owned 37,103 shares of the company’s stock, valued at $504,600.80. This represents a 17.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Surgery Partners Stock Performance

Shares of NASDAQ SGRY opened at $12.95 on Wednesday. The business’s 50-day simple moving average is $15.10 and its 200-day simple moving average is $17.93. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. Surgery Partners, Inc. has a 52 week low of $12.25 and a 52 week high of $24.60. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -20.89 and a beta of 1.95.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The company had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same quarter last year, the firm posted $0.44 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, equities research analysts expect that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its Board of Directors has authorized a share buyback program on Thursday, February 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to repurchase up to 9.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Surgery Partners

Several large investors have recently bought and sold shares of SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Surgery Partners by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock worth $1,085,000 after purchasing an additional 2,015 shares during the period. Millennium Management LLC lifted its stake in shares of Surgery Partners by 1,253.7% in the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock valued at $4,804,000 after buying an additional 219,806 shares during the period. Empowered Funds LLC lifted its stake in shares of Surgery Partners by 11.0% in the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock valued at $305,000 after buying an additional 1,278 shares during the period. Envestnet Asset Management Inc. grew its position in Surgery Partners by 7.5% during the second quarter. Envestnet Asset Management Inc. now owns 32,763 shares of the company’s stock worth $728,000 after buying an additional 2,284 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in Surgery Partners by 9.5% during the second quarter. Teacher Retirement System of Texas now owns 20,597 shares of the company’s stock worth $458,000 after buying an additional 1,780 shares in the last quarter.

Trending Headlines about Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus remains constructive — several brokerages rate SGRY as a “Moderate Buy,” which supports baseline investor demand. Brokerage Recommendation
• Positive Sentiment: Investor conference access: Management presented at the Barclays 28th Annual Global Healthcare Conference (Mar 10), providing a forum to reiterate guidance and margin improvement plans — useful upside catalyst if commentary is clear and credible. Prepared Remarks Transcript
• Positive Sentiment: Short interest fell ~15.7% in February (still ~11% of float but lower than mid‑month), which reduces one source of bearish positioning and could limit further short-driven price pressure.
• Neutral Sentiment: Prepared remarks and Q4 write‑ups: Recent transcripts and industry Q4 summaries provide more detail on volumes and outpatient trends but contain no single new, market‑moving disclosure. Q4 Coverage
• Negative Sentiment: Activist pressure: Ortelius Capital is pushing for board changes and asset sales, increasing the chance of near‑term strategic disruption, management turnover or contentious proxy fights. Activist Story
• Negative Sentiment: Fraud probe announced: Law firm Levi & Korsinsky opened an investigation into prior management statements on margin expansion, raising potential legal/settlement risk and heightening investor uncertainty. Fraud Investigation
• Negative Sentiment: Significant insider selling: Multiple executives (CEO, CFO and other officers) sold sizable blocks the week of Mar 5–6 at roughly $13.60–$13.93, which the market often interprets negatively for near‑term confidence. Representative SEC filing: CEO Sale Filing
• Negative Sentiment: Recent earnings execution: The March 2 Q4 report showed a meaningful EPS miss (revenue slight beat but EPS well below street), highlighting execution/margin risk that underpins some of the legal and activist scrutiny.

Analysts Set New Price Targets

SGRY has been the subject of a number of research analyst reports. Barclays cut their target price on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 4th. JPMorgan Chase & Co. cut their price objective on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Finally, UBS Group lowered their target price on Surgery Partners from $29.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.60.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.